Trial Profile
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 27 Jan 2016 New trial record